Kufor–Rakeb syndrome

Kufor–Rakeb syndrome (KRS) is a rare, inherited neurodegenerative disorder characterized by early-onset parkinsonism, pyramidal degeneration, and cognitive decline. It is also known as Parkinsonism with spasticity, and it is classified as a form of juvenile parkinsonism.
Presentation
Kufor–Rakeb syndrome typically presents in childhood or adolescence. The primary symptoms include parkinsonism, which manifests as bradykinesia, rigidity, and tremor. Additionally, patients often exhibit spasticity, which is an abnormal increase in muscle tone or stiffness. Cognitive decline is also a significant feature, leading to progressive dementia. Other symptoms may include supranuclear gaze palsy, hyperreflexia, and dystonia.
Genetics
Kufor–Rakeb syndrome is caused by mutations in the ATP13A2 gene, which encodes a lysosomal P-type ATPase. This gene is located on chromosome 1p36. The disorder is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to develop the condition.
Pathophysiology
The ATP13A2 protein is involved in the regulation of lysosomal function and ion homeostasis. Mutations in the ATP13A2 gene lead to lysosomal dysfunction, which contributes to the neurodegenerative process observed in Kufor–Rakeb syndrome. The exact mechanisms by which these mutations cause the clinical features of the syndrome are still under investigation.
Diagnosis
Diagnosis of Kufor–Rakeb syndrome is based on clinical evaluation, family history, and genetic testing to identify mutations in the ATP13A2 gene. Neuroimaging studies, such as MRI and CT scans, may show brain atrophy, particularly in the basal ganglia and cerebellum.
Treatment
There is currently no cure for Kufor–Rakeb syndrome. Treatment is primarily symptomatic and supportive. Levodopa and other dopaminergic medications may provide some relief for parkinsonian symptoms, although their effectiveness is often limited. Physical therapy, occupational therapy, and speech therapy can help manage spasticity and improve quality of life.
Prognosis
The prognosis for individuals with Kufor–Rakeb syndrome is generally poor, with progressive neurological decline leading to severe disability. Life expectancy may be reduced, although the rate of progression can vary among individuals.
See also
References
External links
-
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
